Search for a command to run...
Abstract Background The accurate detection of HER2 expression in breast cancer is critical for understanding the pathways of tumor growth and metastasis. While HER2 IHC has many widely accepted applications across multiple tissue types, there remains a need for alternative clones to better characterize the full impact of HER2-dependent pathways on tumor phenotype. We present a comprehensive evaluation of the novel research use-only HER2 IHC clone, BMA, developed by Leica Biosystems, across multiple breast tissue specimens. Methods This study involved the assessment of both normal breast and invasive breast cancer (primary and metastatic) tissue samples. We evaluated morphologic characteristics of the tissue via hematoxylin and eosin staining on the Histocore SPECTRA stainer. Following this evaluation, HER2 IHC staining was performed on the BOND RX from Leica Biosystems. Finally, images were scanned using the Aperio GT 450 to obtain whole slide images (WSIs) for analysis. Evaluation of the WSIs was performed by three independent pathologists. Results Our data demonstrates that the novel BMA clone for HER2 IHC stained cases reproducibly and accurately in terms of intensity, distribution, and specificity. These results were consistent across benign and malignant breast tissue samples. The results also show strong inter- and intra-pathologist concordance, demonstrating that BMA staining can be reliably interpreted across users. These findings highlight the potential of the new BMA clone as a promising new tool for Her2 IHC evaluation in breast cancer, pending further validation. Conclusion While the BMA clone is currently available as a Research Use Only (RUO) product, these preliminary results suggest that it may offer a viable solution for researchers looking for a robust means of Her2 IHC evaluation using the workflow described including the BOND RX from Leica Biosystems and the Aperio GT 450.